Special Issue "Cystic Fibrosis and Personalized Medicine"
Deadline for manuscript submissions: 25 November 2021.
Interests: pediatric respiratory diseases; allergology
Cystic fibrosis is the most prevalent monogenetic disease worldwide. Over 2000 different defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have been described, not only leading to a highly diverse phenotype of the disease, but also to the development of a plethora of gene-defect specific therapies. Many new techniques and models have been developed to unravel the genotype-phenotype relationship and to develop and apply new molecules which can modify CFTR-protein function. In addition to clinical and radiological evaluation, functional measurements such as sweat testing, intestinal current measurements, and patient-derived cell models from airway and gut tissue have become available. Today, these tools are more and more helpful in driving treatment of cystic fibrosis into theratyping and real personalized medicine. For this Special Issue, we invite review articles and original studies addressing the latest developments in patient-specific drug development and evaluation of effects in patients with cystic fibrosis.
Prof. Dr. Cornelis K. van der Ent
Prof. Dr. Harry G. M. Heijerman
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cystic fibrosis
- cystic fibrosis transmembrane conductance regulator
- cell models